Amantadine: Additional Phase III data

Additional data from the double-blind, U.S. and Canadian Phase III EASE LID trial in 126 patients with moderate to advanced PD with levodopa-induced dyskinesia showed

Read the full 250 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE